NFGH
BCRX icon

Nan Fung Group Holdings’s BioCryst Pharmaceuticals BCRX Stock Holding History

Nan Fung Group Holdings’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-36,847
Closed -$187K – 45
2024
Q1 		$187K Buy
36,847
+19,000
+106% +$107K 0.17% 41
2023
Q4 		$107K Hold
17,847
– – 0.07% 34
2023
Q3 		$126K Hold
17,847
– – 0.1% 34
2023
Q2 		$126K Hold
17,847
– – 0.08% 40
2023
Q1 		$149K Buy
+17,847
New +$172K 0.1% 38
2022
Q1 		– Sell
-15,545
Closed -$215K – 47
2021
Q4 		$215K Buy
+15,545
New +$206K 0.06% 46

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Nan Fung Group Holdings's BCRX Position: Q2 2024 in Review

Nan Fung Group Holdings sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 36,847 shares — an estimated $187K sold.

Nan Fung Group Holdings first reported a position in BCRX in Q4 2021 and held it in 6 quarters. The position peaked at $215K in Q4 2021. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • Nan Fung Group Holdings reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Nan Fung Group Holdings sold 36,847 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $187K.
  • Nan Fung Group Holdings first reported a position in BioCryst Pharmaceuticals in Q4 2021 and held it in 6 quarters.
  • Nan Fung Group Holdings's BioCryst Pharmaceuticals position peaked at $215K in Q4 2021.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on Nan Fung Group Holdings's 13F filing for Q2 2024, filed 13 Aug 2024.